16.08.2019 • News

ACG Acquires Pharma Processing Equipment Provider Xertecs

ACG Engineering has acquired Germany-based pharma processing equipment company...
ACG Engineering has acquired Germany-based pharma processing equipment company Xertecs. © Xertecs/ACG

ACG Engineering (ACGE), part of India-headquartered ACG group, has acquired Germany-based pharma processing equipment company Xertecs. The deal, which entails ACG acquiring 100% of the shares, follows a previous partnership between the two companies.

The Xertecs facility and team in Muellheim, Germany will become a key center of excellence to serve as ACG Innovation Centre Europe

Richard Stedman, group CEO, ACG Engineering, said: “This is a tremendous boost for our commitment to create next-generation machines that serve our pharmaceutical and nutraceutical customers. The Xertecs team brings best-in-class design and product management skills to ACG Engineering. We are looking forward to developing a wide range of innovative, ground-breaking equipment solutions and best-practice initiatives between the two teams.”

Klaus Groeschel, managing director, Sales & Marketing for Xertecs added: “This represents a great opportunity for ACG to meet global design standards throughout its product portfolio. This is the next logical step in the relationship between our two businesses. The team at Xertecs is very enthusiastic for the opportunity to continue contributing to ACG’s global product offerings and service capabilities.”

The German company develops and implements processes, products and services for pharma companies around the world. Its portfolio includes conceptualization; design engineering; prototype development; automation design and integration into MES systems; development and optimization of components; complete plant design including 3D modeling, and process optimization and delivery of new process equipment.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.